Abstract:Background Severe respiratory system illness caused by influenza A virus infection is associated with excessive inflammation and abnormal apoptosis in alveolar epithelial cells (AEC). However, there are limited therapeutic options for influenza-associated lung inflammation and apoptosis. Pterostilbene (PTE, trans-3,5-dimethoxy-4-hydroxystilbene) is a dimethylated analog of resveratrol that has been reported to limit influenza A virus infection by promoting antiviral innate immunity, but has not been studied for its protective effects on virus-associated inflammation and injury in AEC. Purpose Our study aimed to investigate the protective effects and underlying mechanisms of PTE in modulating inflammation and apoptosis in AEC, as well as its effects on macrophage polarization during influenza virus infection. Study design and methods A murine model of influenza A virus-mediated acute lung injury was established by intranasal inoculation with 5LD 50 of mouse-adapted H1N1 viruses. Hematoxylin and eosin staining, immunofluorescence, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, western blotting, Luminex and flow cytometry were performed. Results PTE effectively mitigated lung histopathological changes and injury induced by H1N1 viruses in vivo . These beneficial effects of PTE were attributed to the suppression of inflammation and apoptosis in AEC, as well as the modulation of M1 macrophage polarization. Mechanistic investigations revealed that PTE activated the phosphorylated AMP-activated protein kinase alpha (P-AMPKα)/sirtui1 (Sirt1)/PPARγ coactivator 1-alpha (PGC1α) signal axis, leading to the inhibition of nuclear factor kappa-B (NF-κB) and p38 mitogen-activated protein kinase (MAPK) signaling induced by H1N1 viruses, thereby attenuating inflammation and apoptosis in AEC. PTE also forced activation of the P-AMPKα/Sirt1/PGC1α signal axis in RAW264.7 cells, counteracting the activation of phosphorylated signal transducer and activator of transcription 1 (P-STAT1) induced by H1N1 viruses and the augment of P-STAT1 activation in RAW264.7 cells with interferon-gamma (IFN-γ) pretreatment before viral infection, thereby reducing H1N1 virus-mediated M1 macrophage polarization as well as the enhancement of macrophages into M1 phenotypes elicited by IFN-γ pretreatment. Additionally, the promotion of the transition of macrophages towards the M2 phenotype by PTE was also related to activation of the P-AMPKα/Sirt1/PGC1α signal axis. Moreover, co-culturing non-infected AEC with H1N1 virus-infected RAW264.7 cells in the presence of PTE inhibited apoptosis and tight junction disruption, which was attributed to the suppression of pro-inflammatory mediators and pro-apoptotic factors in an AMPKα-dependent manner. Conclusion In conclusion, our findings suggest that PTE may serve as a promising novel therapeutic option for treating influenza-associated lung injury. Its ability to suppress inflammation and apoptosis in AEC, modulate macrophage polarization, and preserve alveolar epithelial cell integrity highlights its potential as a therapeutic agent in influenza diseases.

Delayed Angiopoietin‐2 Blockade Reduces Influenza‐induced Lung Injury and Improves Survival in Mice

Plasma surfactant proteins and lipid mediators in the airway associate with different stages of viral infection and resolution in a sub-lethal mouse Influenza A model

Bioinformatic analysis of PD 1 checkpoint blockade responsive immune microenvironment in severe influenza infection

Postexposure Liponucleotide Prophylaxis and Treatment Attenuates Acute Respiratory Distress Syndrome in Influenza-infected Mice

TGF-βR2 signaling coordinates pulmonary vascular repair after viral injury in mice and human tissue

Angiotensin II Plasma Levels Are Linked to Disease Severity and Predict Fatal Outcomes in H7N9-infected Patients.

Angiotensin-converting Enzyme 2 (ACE2) Mediates Influenza H7N9 Virus-Induced Acute Lung Injury

AIM2 Inflammasome is Critical for Influenza-Induced Lung Injury and Mortality.

RETRACTION: Anisodamine (654-2) inhibits inflammation to alleviate influenza A virus-induced acute lung injury (Retraction of 2021)

Basic Fibroblast Growth Factor Protects Against Influenza A Virus-Induced Acute Lung Injury by Recruiting Neutrophils.

Retraction Note: Combination of Sphingosine-1-phosphate Receptor 1 (S1PR1) Agonist and Antiviral Drug: a Potential Therapy Against Pathogenic Influenza Virus

Insights into the mechanism of action of pterostilbene against influenza A virus-induced acute lung injury

Postinfection A77-1726 treatment improves cardiopulmonary function in H1N1 influenza-infected mice

Inhibition of Autophagy Ameliorates Acute Lung Injury Caused by Avian Influenza A H5N1 Infection

Role of IL-17-EGFR axis in alleviated lung inflammation and recovery during the late phase of acute influenza virus infection

A Panel of Janus Kinase Inhibitors Identified with Anti-Inflammatory Effects Protect Mice from Lethal Influenza Virus Infection.

A New Therapeutic Strategy for Lung Tissue Injury Induced by Influenza with Cr2 Targeting Complement Inhibitior

Galectin-1 Ameliorates Influenza A H1N1pdm09 Virus-Induced Acute Lung Injury.

Osteopontin aggravates acute lung injury in influenza virus infection by promoting macrophages necroptosis

Two waves of pro-inflammatory factors are released during the influenza A virus (IAV)-driven pulmonary immunopathogenesis

Ifenprodil and Flavopiridol Identified by Genome-Wide RNAi Screening As Effective Drugs to Ameliorate Murine Acute Lung Injury after Influenza A H5N1 Virus Infection